Unither

Pharmaceutical CDMO

Investment – Divestment

2006 – …

Turnover

€475M
  • Unither is one of the world’s leading manufacturers of niche dosage forms for pharmaceutical companies and the world leader in blow-fill-seal (BFS) technology.
  • Parquest invested in Unither as part of a secondary MBO alongside the management team.
  • Since its creation, the group has pursued a development strategy aimed at strengthening its leadership and international presence through internal and external growth. It currently operates 5 plants in France, the US, Brazil and China and 1 R&D center.
  • Parquest has been supporting the management team since 2006: as a majority shareholder from 2006 to 2011 and as a minority shareholder since then through successive MBO operations alongside Eric Goupil and his team. In early 2023, Parquest reinvested in Unither as part of a consortium of funds, including GIC, IK and Keensight.
Sector
Health & Care
www.unither-pharma.com

The dedicated team

Laurence Bouttier

Partner

Adrien David

Investment Manager

Denis Le Chevallier

Partner

Vincent Warlop

Partner

Related articles

10 / 2022
Press Release
Parquest is supporting Unither in its next growth cycle
11 / 2020
Press Release
Unither's acquisition in China
03 / 2017
Press Release
Parquest Capital renews its support to Unither group
01 / 2016
Press Release
Build-up - Unither Pharmaceuticals acquires a brazilian manufacturer